Hemostemix Inc. (HEM.V) Research

Hemostemix Inc. is a biotechnology firm specializing in the creation, production, and distribution of treatments derived from blood stem cells to address various health issues. These innovative cell therapies are uniquely sourced from a patient's own blood, offering a minimally invasive method to obtain therapeutic cells. The company's primary therapeutic candidate is ACP-01. This autologous (patient's own cells) treatment is currently undergoing Phase II clinical trials in both Canada and the United States. Its primary focus is the treatment of critical limb ischemia, but it is also being evaluated for heart and peripheral arterial diseases. Beyond ACP-01, Hemostemix is actively researching and advancing other distinct cell product lines, including synergistic cell populations and precursors for neural cells. Its corporate headquarters are situated in Calgary, Canada.

Market snapshot

Symbol
HEM.V
Price
$0.05
Day change
+0.00%
Market cap
$9.9M
P/E ratio
-2.11x
52-week range
0.04-0.16
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Britannia Life Sciences Inc. (BLAB.CN)
  • Rapid Dose Therapeutics Corp. (DOSE.CN)
  • Pharmala Biotech Holdings Inc. (MDMA.CN)
  • Marvel Biosciences Corp. (MRVL.V)
  • Pangenomic Health Inc. (NARA.CN)
  • PreveCeutical Medical Inc. (PREV.CN)
  • Red White & Bloom Brands Inc. (RWB.CN)
  • Telescope Innovations Corp. (TELI.CN)

Open Hemostemix Inc. (HEM.V) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.